Welcome to our dedicated page for Sophia Genetics Sa news (Ticker: SOPH), a resource for investors and traders seeking the latest updates and insights on Sophia Genetics Sa stock.
SOPHiA GENETICS SA (SOPH) is a leader in AI-powered genomic analysis, enabling data-driven healthcare through its cloud-native SOPHiA DDM™ Platform. This page aggregates official company news and press releases, providing stakeholders with timely updates on advancements in precision medicine.
Access curated information on financial results, strategic partnerships, and technology innovations that shape the future of clinical diagnostics. Track developments in oncology solutions, regulatory milestones, and research collaborations across their global network of 1,000+ healthcare institutions.
Our repository includes updates on:
- FDA-cleared genomic profiling tools
- AI-driven diagnostic platform enhancements
- Cross-industry research initiatives in rare diseases
- Operational expansions and executive appointments
Bookmark this page for streamlined access to verified SOPHiA GENETICS updates, combining Swiss precision with cutting-edge analytics to transform patient care worldwide.
Rhea-AI Summary
SOPHiA GENETICS and UroCCR collaborate on a study using a multimodal algorithm to predict post-operative outcomes for renal cell carcinoma patients. The AI model outperformed usual prognostic scores, showing the potential of AI in cancer research.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.94%
Tags
-
Rhea-AI Summary
SOPHiA GENETICS (SOPH) CFO and COO to speak at Barclays Global Healthcare Conference on March 13, 2024. Webcast available on Investor Relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.4%
Tags
-
Rhea-AI Summary
SOPHiA GENETICS reports strong financial performance in Q4 2023 and FY 2023 with record revenue, customer additions, and cash burn decline. Revenue grew 27% in Q4 and 31% for FY 2023, with improved gross margins and operating loss. Cash burn decreased by 36% year-over-year. The company signed 35 new customers in Q4 2023 and expanded its presence in the U.S. market. SOPHiA DDM™ platform saw significant growth and adoption, with new applications and partnerships driving revenue. The company aims for continued growth in 2024 and profitability in the next 2+ years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.36%
Tags
News
Rhea-AI Summary
SOPHiA GENETICS (SOPH) executives to participate in fireside chat at 44th Annual TD Cowen Health Care Conference. The chat will be webcast live on the company's Investor Relations website, with a replay available post-event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.42%
Tags
-
Rhea-AI Summary
SOPHiA GENETICS (SOPH) will release its financial results for Q4 and full-year 2023 on March 5, 2024. The company, known for data-driven medicine, will host a conference call to discuss the results and business outlook.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.68%
Tags
-
Rhea-AI Summary
SOPHiA GENETICS and AstraZeneca Spain have expanded their HRD testing program in Spain to support the molecular diagnosis of ovarian cancer. The program aims to increase access to local testing for homologous recombination deficiency (HRD) throughout the country, with the goal of making vital testing available to thousands more patients. AstraZeneca Spain has named SOPHiA GENETICS its preferred partner in deploying HRD testing throughout Spain, offering the option for HRD testing to become available to more laboratories. The collaboration aims to increase accelerated diagnostics for patients and support clinicians in precision treatment planning.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
SOPHiA GENETICS (SOPH) announced a collaboration with Bioma4me, a Brazil-based company focused on genetic sequencing to drive precision medicine in Brazil. Bioma4me will use SOPHiA DDM™ Platform to advance and streamline its genetic testing capabilities, enabling fast turnaround time for results and full ownership over its data. Through this partnership, Bioma4me aims to advance the field of oncology, microbiome, and genetic diseases in Latin America.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.32%
Tags
-
Rhea-AI Summary
RareCyte Inc. has partnered with SOPHiA GENETICS to implement the SOPHiA DDM™ Platform for its Precision Biology Services portfolio. This partnership will enable RareCyte to provide DNA sequencing of circulating tumor cells and cell-free DNA for cancer patient testing, supporting the advancement of oncology, immuno-oncology, maternal-fetal health, and cell and gene therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.74%
Tags
-
Rhea-AI Summary
SOPHiA GENETICS partners with Karkinos Healthcare to advance cancer research and personalized cancer care in India. The partnership aims to expand access to precision oncology and equip local health institutions with the tools and technology needed to practice data-driven medicine. Karkinos Healthcare will use the SOPHiA DDM™ Platform to advance research and streamline workflow for a variety of blood cancers and solid tumors, with a focus on precision medicine for the underprivileged population of India.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.62%
Tags
Rhea-AI Summary
SOPHiA GENETICS (Nasdaq: SOPH) reports continued revenue growth driven by strong adoption and analysis volume of the SOPHiA DDM™ Platform. The company will present its near-term growth strategy at the 42nd annual J.P. Morgan Healthcare Conference, highlighting a record 315,000+ analyses globally in 2023, with over 1.5 million genomic profiles analyzed worldwide. New customer count for 2023 includes 87 core genomics customers globally, resulting in a current network of 750+ customers using SOPHiA DDM™ globally. The company also announced new U.S.-based customer Tennessee Oncology exploring MSK-ACCESS® powered with SOPHiA DDM™, Latin American healthcare network Dasa expanding to incorporate the liquid biopsy application, and The Royal Marsden live on the SOPHiA DDM™ Platform to support HRD testing and research.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Sophia Genetics Sa